ADAM10 is a potential biomarker for Alzheimer's disease (AD). ADAM10 protein levels are reduced in platelets of AD patients. The aim was to verify the total blood and platelet ADAM10 gene expression in AD patients and to compare with mild cognitive impairment (MCI) and healthy subjects. No significant differences in ADAM10 gene expression were observed. Therefore, the decrease of ADAM10 protein in platelets of AD patients is not caused by a reduction in ADAM10 mRNA. Further studies must be performed to investigate other pathways in the down regulation of ADAM10 protein.
ADAM10 gene expression in the blood cells of Alzheimer's disease patients and mild cognitive impairment subjects / P.R. Manzine, E. Marcello, B. Borroni, W. Kamphuis, E. Hol, A. Padovani, C.C. Nascimento, P. De Godoy Bueno, F. Assis Carvalho Vale, S.C. Iost Pavarini, M. Di Luca, M.R. Cominetti. - In: BIOMARKERS. - ISSN 1354-750X. - 20:3(2015), pp. 196-201. [10.3109/1354750X.2015.1062554]
ADAM10 gene expression in the blood cells of Alzheimer's disease patients and mild cognitive impairment subjects
E. Marcello;M. Di Luca;
2015
Abstract
ADAM10 is a potential biomarker for Alzheimer's disease (AD). ADAM10 protein levels are reduced in platelets of AD patients. The aim was to verify the total blood and platelet ADAM10 gene expression in AD patients and to compare with mild cognitive impairment (MCI) and healthy subjects. No significant differences in ADAM10 gene expression were observed. Therefore, the decrease of ADAM10 protein in platelets of AD patients is not caused by a reduction in ADAM10 mRNA. Further studies must be performed to investigate other pathways in the down regulation of ADAM10 protein.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1354750X.2015.pdf
non disponibili |
445.03 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
